The European Medicines Agency’s Emergency Task Force (ETF), based on a clinical trial involving 500 volunteers, advised on 19 August that Bavarian Nordic’s Imvanex monkeypox vaccine (see EUROPE B12998A24) should be administered intradermally.
Volunteers in the study produced the same level of antibodies after intradermal injection with 1/5 of the vaccine dose as volunteers vaccinated subcutaneously with a full dose of the same vaccine. Intradermal administration is therefore an...